Read Larry Connors' blog – Short Term Trading Strategies
NorthEstoniaRegionalHospital, which serves two-thirds of Estonia's 1.4 million population, has doubled its linear accelerator capacity with the acquisition of a Varian Clinac DHX equipped with a Millennium 120-leaf collimator, enabling more conformal radiotherapy treatment. "We have moved from conventional radiotherapy to conformal radiotherapy for the first time," says senior physicist Eduard Gerskevitch. "The collimator's finer leaves allow clinicians to conform the treatment beam tighter to the tumor and limit irradiation of normal healthy tissue.
"This new equipment has enabled us to improve the quality of our treatments while reducing waiting lists. Our waiting times have reduced from five weeks to three weeks, although we've achieved this with a heavy workload on our machines."
This workload increased shortly after the new machine arrived when an older device at the only other Estonian radiotherapy hospital broke down and all that hospital's patients were transferred to the NorthEstonianRegionalHospital. "At present we are the only hospital in the country treating patients with a linear accelerator and we are extremely busy," said Maire Kuddu, chief radiation oncologist. Staff at the hospital are working double-shift on both machines as they attempt to cope with more than 130 patients a day.
Despite this heavy workload, the team has been able to introduce advanced IMRT for head and neck cancer patients. Intensity modulated radiotherapy enables clinicians to 'sculpt' the dose to the shape of the tumor and avoid more surrounding healthy tissue. For head and neck patients, it means more precise treatments and less potential harm to nearby salivary and parotid glands.
The new device was funded by the hospital with support from the International Atomic Energy Agency, which provided additional financing and helped to train staff in the use of the equipment, and the Environmental Investment Centre, which helped to decommission an older Cobalt-based treatment unit and refurbish the bunker for the new accelerator.
"We are delighted to be able to double both our own and the country's linear accelerator treatment capacity and introduce advanced radiotherapy techniques at the same time," adds Maire Kuddu. She said the hospital's future plans include equipping the new machine with an On-Board Imager and introducing Varian's RapidArc capability for fast and precise image-guided IMRT.
"It is recognised that this is a major improvement in the country's cancer treatment capabilities but this is just a start," added Eduard Gerskevitch. "The number of treatment units is still very low compared with our needs and we will need to see further investment in radiotherapy in the future."
About Varian Medical Systems
Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 4,800 people who are located at manufacturing sites in North America and Europeand in its 60 sales and support offices around the world.
CONTACT: Neil Madle, Varian Medical Systems Tel: +44 (0)7786 526 068 WWW: http://www.varian.com
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
The Connors Group, Inc. ("Company") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities or currencies customers should buy or sell for themselves. The analysts and employees or affiliates of Company may hold positions in the stocks, currencies or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities and/or currencies. The Company, the authors, the publisher, and all affiliates of Company assume no responsibility or liability for your trading and investment results. Factual statements on the Company's website, or in its publications, are made as of the date stated and are subject to change without notice.
It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by Company are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of Company's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on Company's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.
HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN INHERENT LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING AND MAY NOT BE IMPACTED BY BROKERAGE AND OTHER SLIPPAGE FEES. ALSO, SINCE THE TRADES HAVE NOT ACTUALLY BEEN EXECUTED, THE RESULTS MAY HAVE UNDER- OR OVER-COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFITS OR LOSSES SIMILAR TO THOSE SHOWN.
The Connors Group, Inc.
10 Exchange Place, Suite 1800
Jersey City, NJ 07302
© Copyright 2009 The Connors Group, Inc.
